曲美他嗪对冠心病急性心力衰竭患者心功能、血清N末端B型利钠肽前体及心肌肌钙蛋白I水平的影响

Abstract
Figure/Table
References (21)
Related Citation (12)

Download: PDF (491 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the influence of Trimetazidine on the cardiac function and levels of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin I (cTn-I) in patients with coronary heart disease and acute heart failure. Methods The clinical data of 96 cases of patients with coronary heart disease and acute heart failure admitted to ICU of the Second People's Hospital of Deyang City from February 2014 to March 2017 was analyzed retrospectively, and they were divided into control group and observation group by different treatment methods. 46 cases of control group were given diuretic Furosemide and vasodilator Nitroglycerin, and 50 cases of observation group were given diuretic Furosemide and vasodilator Nitroglycerin and Trimetazidine. Both groups were treated continuously for 7 d. Before and after treatment, the cardiac functional grading, the levels of NT-proBNP and cTn-I, and the clinical effects of two groups were observed. Results There were no statistically significant differences of cardiac functional grading, the levels of NT-proBNP and cTn-I between the two groups before treatment (P ＞ 0.05). After treatment, the cardiac functional grading of the two groups was better than that before treatment, and the levels of NT-proBNP and cTn-I in the two groups were lower than those before treatment, and the cardiac functional grading of observation group was better than that of control group, the levels of NT-proBNP and cTn-I in the observation group were lower than those of control group, the differences were statistically significant (P ＜ 0.05). The total effective rate of observation group was higher than that of the control group, the difference was statistically significant (P ＜ 0.05). Conclusion Trimetazidine in the treatment of patients with coronary heart disease and acute heart failure can significantly improve cardiac function, decrease the levels of serum NT-proBNP and cTn-I, with good curative effect, which is worthy of clinical promotion and application.

Key words： Trimetazidine Coronary heart disease Acute heart failure Cardiac function N-terminal type B natriuretic peptide precursor Cardiac troponin I

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Hailong WANG Jun LIANG Yi ZHANG Yi WU Juan

Cite this article:

ZHU Hailong WANG Jun LIANG Yi ZHANG Yi WU Juan. The influence of Trimetazidine on the cardiac function and levels of serum NT-proBNP and cTn-I in patients with coronary heart disease and acute heart failure[J]. 中国医药导报, 2018, 15(5): 62-65.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I5/62

[1] 刘念念，唐康庭，肖平喜.急性心力衰竭患者血浆BNP水平变化与心功能及预后的关系[J].心血管康复医学杂志，2017，26（4）：364-367.
[2] 曾爱辉，马建林，张敬文，等.重组人脑利钠肽联合多巴胺治疗急性心力衰竭并低血压患者的临床效果观察[J].中国循证心血管医学杂志，2017，9（8）：951-953，956.
[3] Suyama JA，Sakloth F，Kolanos R，et al. Abuse-Related Neurochemical Effects of Para-Substituted Methcathinone Analogs in Rats：Microdialysis Studies of Nucleus Accumbens Dopamine andSerotonin [J]. J Pharmacol Exp Ther，2016，356（1）：182-190.
[4] 王治洲.曲美他嗪联合美托洛尔治疗冠心病心力衰竭的临床疗效及其对血清高敏心肌肌钙蛋白T、脑钠肽水平的影响研究[J].实用心脑肺血管病杂志，2017，25（1）：121-122.
[5] Schaeffer E，Berg D. Cycling' with long-acting dopamine agonists for augmentation in restless legs syndrome [J]. Eur J Neurol，2016，23（3）：e17-e18.
[6] 胡大一.心脏病学实践[M].北京：人民卫生出版社，2003：322-327.
[7] 阿不来提·海里力，张红玉，文进.急性心力衰竭患者血浆氨基末端脑钠肽前体浓度与心功能分级的相关性[J].岭南心血管病杂志，2017，23（3）：294-297.
[8] Stienen S，Salah K，Eurlings LW，et al. Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients：absolute or relative discharge levels [J]. Eur J Heart Fail，2015，17（9）：936-944.
[9] 张爱文，侯瑞田，霍明艳，等.盐酸曲美他嗪对老年舒张性心力衰竭患者同型半胱氨酸及B型脑利钠肽水平的影响[J].中国药业，2015，24（23）：88-90.
[10] Salah K，Pinto YM，Eurlings LW，et al. Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality，independent of N-terminal pro-B-type natriuretic peptide levels：An individual patient data analysis [J]. Am Heart J，2015，170（3）：531-542.
[11] 刘秀叶，崔炜，谢瑞芹，等.基础血浆B型利钠肽水平对心力衰竭患者应用重组人B型利钠肽短期临床疗效的预测价值[J].中国心血管病杂志，2017，22（4）：243-247.
[12] Leto L，Testa M，Feola M. The predictive value of plasma biomarkers in discharged heart failure patients：role of plasma NT-proBNP [J]. Minerva Cardioangiol，2016，64（2）：157-164.
[13] 邵丽川.曲美他嗪对慢性心力衰竭患者血清肌酸激酶同工酶、脑利钠肽及神经肽Y水平影响研究[J].临床和实验医学杂志，2016，15（16）：1598-1601.
[14] Scrutinio D，Ammirati E，Passantino A，et al. Predicting short-term mortality in advanced decompensated heart failure-role of the updated acute decompensated heart failure/N-terminal pro-B-type natriuretic peptide risk score [J]. Circ J，2015，79（5）：1076-1083.
[15] 徐正平，蒋煜.冻干重组人脑利钠肽联合盐酸曲美他嗪治疗老年慢性收缩性心力衰竭[J].交通医学，2014，28（6）：658-659.
[16] Martindale JL，Wakai A，Collins SP，et al. Diagnosing acute heart failure in the emergency department：a systematic review and meta-analysis [J]. Acad Emerg Med，2016， 23（3）：223-242.
[17] 何艳丽，祖秀光，乔福斌，等.曲美他嗪联合冻干重组人脑利钠肽治疗慢性充血性心力衰竭对患者超声心动图和心功能的影响[J].海南医学，2015，26（6）：790-793.
[18] Vodovar N，Séronde MF，Laribi S，et al. Post-trans-lational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure [J]. Eur Heart J，2014，35（48）：3434-3441.
[19] 黄炳林.参附注射液与左西孟旦联用治疗急性心力衰竭患者的疗效及其对炎性因子和脑利钠肽指标的影响[J].抗感染药学，2017，14（3）：622-624.
[20] 刘泉，张淼，沈红军.慢性心力衰竭病人血清和肽素及N末端B型利钠肽原浓度变化及其临床意义[J].中西医结合心脑血管病杂志，2017，15（16）：2015-2018.
[21] 王明秀，周仕鸿，王月月，等.曲美他嗪联合利尿剂对慢性心力衰竭患者心功能及血清N末端B型利钠肽前体、心肌肌钙蛋白I水平的影响[J].实用心脑肺血管病杂志，2017，25（8）：121-123.